NI202000036A - Anticuerpo específicos para el transcrito semillar a la inmunoglobulina tipo 3 (ilt3) y sus usos. - Google Patents
Anticuerpo específicos para el transcrito semillar a la inmunoglobulina tipo 3 (ilt3) y sus usos.Info
- Publication number
- NI202000036A NI202000036A NI202000036A NI202000036A NI202000036A NI 202000036 A NI202000036 A NI 202000036A NI 202000036 A NI202000036 A NI 202000036A NI 202000036 A NI202000036 A NI 202000036A NI 202000036 A NI202000036 A NI 202000036A
- Authority
- NI
- Nicaragua
- Prior art keywords
- ilt3
- transcript
- seed
- specific antibody
- immunoglobulin type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen anticuerpos monoclonales no promiscuos humanizados específicos para el transcrito similar a la inmunoglobulina tipo 3 (ILT3), también conocido como receptor de tipo inmunoglobulina de leucocitos de la subfamilia B miembro 4 (LILRB4).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762587604P | 2017-11-17 | 2017-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI202000036A true NI202000036A (es) | 2020-09-24 |
Family
ID=64572590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI202000036A NI202000036A (es) | 2017-11-17 | 2020-05-08 | Anticuerpo específicos para el transcrito semillar a la inmunoglobulina tipo 3 (ilt3) y sus usos. |
Country Status (26)
Country | Link |
---|---|
US (6) | US11111297B2 (es) |
EP (1) | EP3710479A2 (es) |
JP (1) | JP7194481B2 (es) |
KR (1) | KR102478433B1 (es) |
CN (1) | CN111712518A (es) |
AR (1) | AR113696A1 (es) |
AU (1) | AU2018367524B2 (es) |
BR (1) | BR112020009759A8 (es) |
CA (1) | CA3082409A1 (es) |
CL (1) | CL2020001240A1 (es) |
CO (1) | CO2020006405A2 (es) |
CR (1) | CR20200204A (es) |
DO (1) | DOP2020000074A (es) |
EA (1) | EA202091228A1 (es) |
EC (1) | ECSP20032082A (es) |
GE (1) | GEP20237565B (es) |
IL (1) | IL274574A (es) |
JO (1) | JOP20200131A1 (es) |
MA (1) | MA50900A (es) |
MX (1) | MX2020005128A (es) |
NI (1) | NI202000036A (es) |
PE (1) | PE20210475A1 (es) |
PH (1) | PH12020550890A1 (es) |
SG (1) | SG11202004426SA (es) |
TW (1) | TWI816715B (es) |
WO (1) | WO2019099597A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0812913B8 (pt) | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos |
KR20220130671A (ko) | 2019-12-19 | 2022-09-27 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | Ilt3-결합제 및 이의 사용 방법 |
AU2022239502A1 (en) * | 2021-03-19 | 2023-10-05 | Merck Sharp & Dohme Llc | Methods for treating cancer with anti-ilt3 antibodies |
WO2023140875A1 (en) * | 2022-01-19 | 2023-07-27 | Ngm Biopharmaceuticals, Inc. | Uses of ilt3-binding agents |
WO2023192850A1 (en) | 2022-03-29 | 2023-10-05 | Ngm Biopharmaceuticals, Inc. | Ilt3 and cd3 binding agents and methods of use thereof |
WO2023209716A1 (en) | 2022-04-25 | 2023-11-02 | Biond Biologics Ltd. | Anti-ilt3 antibodies and use thereof |
WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
CA2122732C (en) | 1991-11-25 | 2008-04-08 | Marc D. Whitlow | Multivalent antigen-binding proteins |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
WO2000032634A1 (en) | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
WO2003000199A2 (en) * | 2001-06-25 | 2003-01-03 | The Trustees Of Columbia University In The City Of New York | Ilt3 and ilt4-related compositions and methods |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
CA2391438A1 (en) | 2002-05-01 | 2003-11-01 | Procyon Biopharma Inc. | Psp94 diagnostic reagents and assays |
CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
EP1799840A4 (en) * | 2004-09-03 | 2009-02-18 | Univ Columbia | ILT3-POLYPEPTIDES AND USES THEREOF |
RU2406760C3 (ru) | 2005-05-09 | 2017-11-28 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
JP5372500B2 (ja) | 2005-06-17 | 2013-12-18 | トレラクス リクイデーティング トラスト | Ilt3結合分子およびその使用 |
CA3018525C (en) | 2005-07-01 | 2023-08-01 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
SI2913343T1 (sl) * | 2005-12-20 | 2019-01-31 | Sbi Biotech Co., Ltd. | Protitelo anti-ILT7 |
WO2007089945A2 (en) | 2006-02-02 | 2007-08-09 | The Trustees Of Columbia University In The City Of New York | Treating diseases by targeting silt3 |
CA2655903A1 (en) * | 2006-06-19 | 2008-08-07 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
GB0705775D0 (en) | 2007-03-26 | 2007-05-02 | Affitech As | Product |
BRPI0812913B8 (pt) | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
DK2242773T3 (en) | 2008-02-11 | 2017-09-25 | Cure Tech Ltd | Monoclonal antibodies for tumor treatment |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
US8114845B2 (en) | 2008-08-25 | 2012-02-14 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
NZ717213A (en) | 2008-12-09 | 2017-10-27 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | Pd−1抗体およびpd−l1抗体ならびにその使用 |
CN101830978A (zh) * | 2009-03-09 | 2010-09-15 | 中国科学院微生物研究所 | 一种人免疫球蛋白样受体突变体及其应用 |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
CA2794708C (en) | 2010-03-29 | 2021-11-16 | Zymeworks Inc. | Antibodies with enhanced or suppressed effector function |
NZ701408A (en) | 2010-04-16 | 2016-01-29 | Medvet Science Pty Ltd | Proteins that bind pi16 and uses thereof |
CA2828289C (en) | 2011-03-29 | 2020-07-21 | Roche Glycart Ag | Antibody fc variants |
WO2013033734A1 (en) | 2011-09-02 | 2013-03-07 | The Trustees Of Columbia University In The City Of New York | Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand |
WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
WO2013181438A2 (en) | 2012-05-30 | 2013-12-05 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for modulating pro-inflammatory immune response |
WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
US9708406B2 (en) | 2013-05-20 | 2017-07-18 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
KR20240056629A (ko) | 2014-09-28 | 2024-04-30 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극성 및 비자극성 골수성 세포의 조절 |
WO2016127427A1 (zh) | 2015-02-15 | 2016-08-18 | 华为技术有限公司 | 电子设备外壳的加工方法、电子设备外壳及电子设备 |
KR102129107B1 (ko) | 2015-03-06 | 2020-07-02 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 항-lilrb 항체 및 암의 검출 및 치료를 위한 이의 용도 |
EP3325006A4 (en) | 2015-07-17 | 2019-03-06 | The Trustees of Columbia University in the City of New York | METHOD FOR TREATING CD166-EXPRESSIVE CANCER |
BR112018010084A2 (pt) | 2015-11-18 | 2018-11-13 | Merck Sharp & Dohme | ligantes de pd1 e/ou lag3 |
SG11201901611YA (en) * | 2016-08-31 | 2019-03-28 | Agency Science Tech & Res | Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof |
WO2018089300A1 (en) | 2016-11-10 | 2018-05-17 | Merck Sharp & Dohme Corp. | Ilt3 ligand |
US11267886B2 (en) | 2017-02-09 | 2022-03-08 | Bluefin Biomedicine, Inc. | Anti-ILT3 antibodies and antibody drug conjugates |
AU2022239502A1 (en) * | 2021-03-19 | 2023-10-05 | Merck Sharp & Dohme Llc | Methods for treating cancer with anti-ilt3 antibodies |
AU2022318734A1 (en) * | 2021-07-28 | 2024-02-08 | Merck Sharp & Dohme Llc | Methods for treating acute myeloid leukemia with anti-ilt3 antibodies |
WO2023017525A1 (en) * | 2021-08-11 | 2023-02-16 | OncoHost Ltd. | Predicting patient response |
WO2023159152A2 (en) * | 2022-02-17 | 2023-08-24 | Immune-Onc Therapeutics, Inc. | Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor |
WO2023235699A1 (en) * | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
WO2024026019A1 (en) * | 2022-07-28 | 2024-02-01 | Merck Sharp & Dohme Llc | Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies |
-
2018
- 2018-11-15 MA MA050900A patent/MA50900A/fr unknown
- 2018-11-15 WO PCT/US2018/061165 patent/WO2019099597A2/en active Application Filing
- 2018-11-15 KR KR1020207016922A patent/KR102478433B1/ko active IP Right Grant
- 2018-11-15 CN CN201880086998.8A patent/CN111712518A/zh active Pending
- 2018-11-15 PE PE2020000691A patent/PE20210475A1/es unknown
- 2018-11-15 CA CA3082409A patent/CA3082409A1/en active Pending
- 2018-11-15 SG SG11202004426SA patent/SG11202004426SA/en unknown
- 2018-11-15 JP JP2020526543A patent/JP7194481B2/ja active Active
- 2018-11-15 GE GEAP201815366A patent/GEP20237565B/en unknown
- 2018-11-15 EA EA202091228A patent/EA202091228A1/ru unknown
- 2018-11-15 TW TW107140611A patent/TWI816715B/zh active
- 2018-11-15 MX MX2020005128A patent/MX2020005128A/es unknown
- 2018-11-15 JO JOP/2020/0131A patent/JOP20200131A1/ar unknown
- 2018-11-15 CR CR20200204A patent/CR20200204A/es unknown
- 2018-11-15 BR BR112020009759A patent/BR112020009759A8/pt unknown
- 2018-11-15 EP EP18812561.1A patent/EP3710479A2/en active Pending
- 2018-11-15 AU AU2018367524A patent/AU2018367524B2/en active Active
- 2018-11-15 AR ARP180103343A patent/AR113696A1/es unknown
- 2018-11-15 US US16/191,485 patent/US11111297B2/en active Active
-
2020
- 2020-05-06 DO DO2020000074A patent/DOP2020000074A/es unknown
- 2020-05-08 NI NI202000036A patent/NI202000036A/es unknown
- 2020-05-10 IL IL274574A patent/IL274574A/en unknown
- 2020-05-11 CL CL2020001240A patent/CL2020001240A1/es unknown
- 2020-05-27 CO CONC2020/0006405A patent/CO2020006405A2/es unknown
- 2020-06-12 EC ECSENADI202032082A patent/ECSP20032082A/es unknown
- 2020-06-15 PH PH12020550890A patent/PH12020550890A1/en unknown
-
2021
- 2021-07-16 US US17/378,070 patent/US20220010011A1/en active Pending
- 2021-07-16 US US17/378,050 patent/US20220010010A1/en active Pending
- 2021-07-16 US US17/378,030 patent/US20220025043A1/en not_active Abandoned
- 2021-07-16 US US17/377,924 patent/US20220025042A1/en not_active Abandoned
- 2021-07-16 US US17/378,000 patent/US20220033497A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI202000036A (es) | Anticuerpo específicos para el transcrito semillar a la inmunoglobulina tipo 3 (ilt3) y sus usos. | |
BR112022010206A2 (pt) | Receptores de antígeno quiméricos e usos dos mesmos | |
CL2020000938A1 (es) | Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744) | |
CY1125008T1 (el) | Χιμαιρικοι υποδοχεις αντιγονων που στοχευουν συζευγμενους με πρωτεϊνη g yποδοχεις και χρησεις αυτων | |
BR112017020894A2 (pt) | imunoreceptores específicos claudina-18.2 e epítopos de células t | |
CO2018001405A2 (es) | Receptores de antígenos quiméricos basados en anticuerpos de dominio simple | |
CO2019011155A2 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
CL2021001603A1 (es) | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor | |
AU2018258045A1 (en) | Chimeric antibody/T-cell receptor constructs and uses thereof | |
CO2017006740A2 (es) | Anticuerpos anti–cd79b | |
CL2017003195A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso. | |
PH12018500861A1 (en) | Antibody/t-cell receptor chimeric constructs and uses thereof | |
AR105767A1 (es) | Proteínas de fusión de unión a gitr multivalentes y multiespecíficas | |
MX2018008308A (es) | Proteinas de fusion de union a 41bb multivalentes y multiespecificas. | |
CU24475B1 (es) | Receptor de antígeno quimérico con dominio de recepción de antígeno, anticuerpo conjugado y acoplador biespecífico de células t que se unen selectivamente a la región constante del trbc1 | |
NZ741067A (en) | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use | |
AR114284A1 (es) | Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl | |
CL2018003515A1 (es) | Anticuerpos anti-gitr y sus usos. | |
UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
CY1123046T1 (el) | Ζωα εκτος του ανθρωπου που εχουν ανθρωποποιημενους υποδοχεις fc-γ | |
IL284091A (en) | Antibodies neutralize the type 2 immunoglobulin-like leukocyte receptor | |
PH12016501339B1 (en) | Novel anti-netrin-1 antibody | |
MX2020005364A (es) | Anticuerpos anti-ox40 y usos de los mismos. | |
MX2021002750A (es) | Anticuerpos anti-tnfrsf9 y usos de los mismos. | |
MX2021000688A (es) | Anticuerpos anti-cd40 y usos de los mismos. |